Praxis Precision Medicine... (PRAX)
NASDAQ: PRAX
· Real-Time Price · USD
43.48
-0.48 (-1.09%)
At close: Jun 25, 2025, 3:59 PM
43.33
-0.34%
After-hours: Jun 25, 2025, 04:04 PM EDT
-1.09% (1D)
| Bid | 36.1 |
| Market Cap | 885.64M |
| Revenue (ttm) | 8.12M |
| Net Income (ttm) | -212.56M |
| EPS (ttm) | -10.66 |
| PE Ratio (ttm) | -4.08 |
| Forward PE | -3.62 |
| Analyst | Buy |
| Ask | 49 |
| Volume | 94,797 |
| Avg. Volume (20D) | 413,432 |
| Open | 44.10 |
| Previous Close | 43.96 |
| Day's Range | 42.53 - 44.10 |
| 52-Week Range | 26.70 - 91.83 |
| Beta | 2.62 |
About PRAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PRAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PRAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Praxis Precision Medicines Inc. is scheduled to release its earnings on Aug 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-13.08%
Praxis Precision Mediciines shares are trading low...
Unlock content with
Pro Subscription
3 months ago
-40.64%
Praxis Precision Medicines shares are trading lower after the company reported a Q4 EPS miss.
3 months ago · seekingalpha.com
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)Ulixacaltamide's Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrig...